Romi Gupta
YOU?
Author Swipe
View article: Exploring the potential link between ADHD, anxiety, autism, and cancer risk
Exploring the potential link between ADHD, anxiety, autism, and cancer risk Open
Neurodevelopmental and mental health disorders such as autism spectrum disorder (ASD), attention-deficit/hyperactivity disorder (ADHD), and anxiety disorders (AD) are increasingly being studied for their potential links to cancer risk. In …
View article: Loss of EHMT2 enhances NK cell-driven anti-tumor immunity through TGF-β1 suppression
Loss of EHMT2 enhances NK cell-driven anti-tumor immunity through TGF-β1 suppression Open
Natural Killer (NK) cells play a critical role in regulating tumor growth, but our understanding of the mechanisms underlying their anti-tumor activity remains limited. We identified the histone methyltransferase EHMT2 as a key suppressor …
ATAD2 drives melanoma growth and progression and inhibits ferroptosis Open
Melanoma is a highly metastatic form of skin cancer for which current therapies offer limited benefits. We show here that the histone reader ATAD2 is overexpressed in melanoma and predicts poor prognosis, and that the MAP kinase pathway, v…
PDE7A inhibition suppresses triple-negative breast cancer by attenuating de novo pyrimidine biosynthesis Open
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer, associated with poor response to therapies and high mortality. We identify that phosphodiesterase 7A (PDE7A) is overexpressed in the majority of TNBCs, and a h…
m<sup>6</sup>A-driven transcriptomic rewiring in tumor immune surveillance Open
RNA molecules are subject to extensive post-transcriptional modifications that fine-tune their stability, localization, and function. Among the more than 100 known RNA modifications, N6-methyladenosine (m 6 A) is the most abundant internal…
Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment Open
Ovarian cancer remains a leading cause of cancer-related deaths due to late-stage diagnosis and treatment resistance. While surgery and chemotherapy are standard treatments, challenges such as platinum resistance, tumor heterogeneity, and …
Epigenetic regulation of NKG2D ligand and the rise of NK cell-based immunotherapy for cancer treatment Open
Epigenetic modifications influence gene expression and effects cancer initiation and progression. Therefore, they serve as diagnostic and prognostic biomarkers and potential therapeutic targets. Natural Killer (NK) cells, integral to the i…
View article: IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers
IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers Open
Background Oncogenic mutations in the RAS gene are associated with uncontrolled cell growth, a hallmark feature contributing to tumorigenesis. While diverse therapeutic strategies have been diligently applied to treat RAS-mutant cancers, s…
Roles and therapeutic targeting of ceramide metabolism in cancer Open
Ceramide-based therapy is a potentially promising approach for cancer therapy. However, overcoming hurdles in pharmacokinetics, specificity, and resistance is needed to optimize its efficacy and safety. This requires comprehensive preclini…
View article: HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B
HOXC6 drives a therapeutically targetable pancreatic cancer growth and metastasis pathway by regulating MSK1 and PPP2R2B Open
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, which lacks effective therapies. Here, we demonstrate that the transcription factor, homeobox C6 (HOXC6), is overexpressed in most PDACs, and its inhibition blocks PD…
View article: Supplementary Methods, Figures S1 - S14, Tables S1, S3 - S10 from A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling
Supplementary Methods, Figures S1 - S14, Tables S1, S3 - S10 from A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling Open
Supplementary Information includes: Supplementary Methods providing additional information on experimental techniques and data analysis; Supplementary Figures S1-S14 providing critical control experiments and raw data analyses for experime…
View article: Supplementary Table S2 from A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling
Supplementary Table S2 from A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling Open
Intensity ratios of methylated to unmethylated DNA for TSG promoters in paired primary hLSCC (LC) and normal lung squamous cell (NL) samples from 18 individuals.
View article: Data from A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling
Data from A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling Open
To discover new tumor-suppressor genes (TSG), we developed a functional genomics approach in which immortalized but nontumorigenic cells were stably transduced with large-scale shRNA pools and tested for tumor formation in mice. Identifica…
View article: Data from A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling
Data from A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling Open
To discover new tumor-suppressor genes (TSG), we developed a functional genomics approach in which immortalized but nontumorigenic cells were stably transduced with large-scale shRNA pools and tested for tumor formation in mice. Identifica…
View article: Supplementary Table S2 from A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling
Supplementary Table S2 from A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling Open
Intensity ratios of methylated to unmethylated DNA for TSG promoters in paired primary hLSCC (LC) and normal lung squamous cell (NL) samples from 18 individuals.
View article: Supplementary Methods, Figures S1 - S14, Tables S1, S3 - S10 from A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling
Supplementary Methods, Figures S1 - S14, Tables S1, S3 - S10 from A Large-Scale RNAi-Based Mouse Tumorigenesis Screen Identifies New Lung Cancer Tumor Suppressors That Repress FGFR Signaling Open
Supplementary Information includes: Supplementary Methods providing additional information on experimental techniques and data analysis; Supplementary Figures S1-S14 providing critical control experiments and raw data analyses for experime…
Supplementary Table S1 from Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies Open
Supplementary Table S1
Data from Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies Open
Cancer is a complex disease and cancer cells typically harbor multiple genetic and epigenetic alterations. Large-scale sequencing of patient-derived cancer samples has identified several druggable driver oncogenes. Many of these oncogenes …
Supplementary Table S1 from Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies Open
Supplementary Table S1
Data from Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies Open
Cancer is a complex disease and cancer cells typically harbor multiple genetic and epigenetic alterations. Large-scale sequencing of patient-derived cancer samples has identified several druggable driver oncogenes. Many of these oncogenes …
CBX5 loss drives EGFR inhibitor resistance and results in therapeutically actionable vulnerabilities in lung cancer Open
Although epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFRi) are approved for treating EGFR-mutant lung adenocarcinoma (LUAD), emergence of acquired resistance limits their clinical benefits. Several mechanisms for a…
View article: UBE2T promotes breast cancer tumor growth by suppressing DNA replication stress
UBE2T promotes breast cancer tumor growth by suppressing DNA replication stress Open
Breast cancer is a leading cause of cancer-related deaths among women, and current therapies benefit only a subset of these patients. Here, we show that ubiquitin-conjugating enzyme E2T (UBE2T) is overexpressed in patient-derived breast ca…
Transcriptional, chromatin, and metabolic landscapes of LDHA inhibitor–resistant pancreatic ductal adenocarcinoma Open
Metabolic reprogramming, due in part to the overexpression of metabolic enzymes, is a key hallmark of cancer cells. Lactate dehydrogenase (LDHA), a metabolic enzyme that catalyzes the interconversion of lactate and pyruvate, is overexpress…
View article: Changes in the Transcriptome and Chromatin Landscape in BRAFi-Resistant Melanoma Cells
Changes in the Transcriptome and Chromatin Landscape in BRAFi-Resistant Melanoma Cells Open
Metastatic and drug-resistant melanoma are leading causes of skin cancer–associated death. Mitogen-associated protein kinase (MAPK) pathway inhibitors and immunotherapies have provided substantial benefits to patients with melanoma. Howeve…
Epigenetic regulation and targeting of ECM for cancer therapy Open
The tumor microenvironment (TME) composed of different types of cells embedded in extracellular matrix (ECM) has crucial effects on cancer growth and metastasis. ECM is made of a variety of proteins that provide structural support to the c…